Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndr...( Two year survival rate of 50.8 p...),Health

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for

conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to

conventional care regimens Only agent to demonstrate survival benefit in MDS compared to conventional

care regimens

Only epigenetic modifier to show survival benefit in cancer

Stratified log-rank p-value = 0.0001, Hazard ratio = 0.58

Largest study ever conducted in higher-risk MDS

BOULDER, Colo., Aug. 2 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced topline results from the multi-institutional, international, randomized, Phase 3 controlled trial of Vidaza(R) (azacitidine for injection) versus conventional care regimens (CCR) in the treatment of patients with higher-risk myelodysplastic syndromes (MDS). In the primary endpoint analysis, Vidaza treatment was associated with a median survival of 24.4 months versus 15 months for those receiving CCR treatment, an improvement of 9.4 months with a stratified log-rank p-value of 0.0001. The hazard ratio describing this treatment effect was 0.58 (95 percent confidence interval of 0.43 to 0.77). Two-year survival rates were 50.8 percent versus 26.2 percent for patients receiving Vidaza versus CCR (p<0.0001). Median number of treatment cycles was nine for Vidaza.

The survival benefits of Vidaza were consistent regardless of the CCR treatment option (best supportive care (BSC) alone, low-dose cytarabine plus BSC or standard chemotherapy plus BSC) utilized in the control arm.

"These landmark results, showing a significant improvement in survival
'/>"/>

SOURCE Pharmion Corporation Copyright©2007 PR Newswire.

3 GOOD